You are a healthy male or female 18-55 years of age
You are able to meet all eligibility criteria
You are able to comply with all study visits
Study number: C1171007
Be compensated for your time: $2650.00 for completion of the study
The Pfizer New Haven Clinical Research Unit is conducting a study of a new investigational drug to treat people with Nonalcoholic Steatohepatitis (NASH). NASH is inflammation of the liver and liver damage caused by buildup of fat in the liver (“fatty liver disease”).
You will be in this study up to about 39 days. This does not include the time between screening and dosing, which can be up to 28 days.
This study involves:
2 dosing periods (during 1 continuous admission)
9 overnight stays
1 follow-up phone call (about 28 to 32 days after the last dose of study drug)